2025
Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial
Khanna S, Yoho D, Van Handel D, Clark B, Awad T, Guthmueller B, Armandi D, Knapple W, Safdar N, Baggott B, Simon K, Feuerstadt P. Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial. Therapeutic Advances In Gastroenterology 2025, 18: 17562848251339697. PMID: 40321366, PMCID: PMC12049624, DOI: 10.1177/17562848251339697.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsPhase IIIb trialAntibiotic treatmentPrevention of recurrent CDINo treatment emergent adverse eventsTreatment successRecurrent Clostridioides difficile infectionClostridioides difficile</i> infectionIntensive care unit admissionParticipation benefitsPrevent CDI recurrenceClostridioides difficile infectionRoute of administrationPhysicians' perceptionsPreventing rCDICDI recurrenceTreatment failureEligible adultsSecondary endpointsFecal microbiotaEffects of fecal microbiotaUnit admissionDifficile infectionAdverse eventsPhysician experience
2024
Predicting positive Clostridioides difficile test results using large-scale longitudinal data of demographics and medication history
Pham A, El-Kareh R, Myers F, Ohno-Machado L, Kuo T. Predicting positive Clostridioides difficile test results using large-scale longitudinal data of demographics and medication history. Heliyon 2024, 11: e41350. PMID: 39958729, PMCID: PMC11825254, DOI: 10.1016/j.heliyon.2024.e41350.Peer-Reviewed Original ResearchArea under the receiver operating characteristic curveMedical historyClostridioides difficile</i> infectionMonths of medical historyPatient's chancesData of demographicsReceiver operating characteristic curveLogistic regression modelsHealth patientsModerate sample sizesPregnant womenHealthcare institutionsClostridioides difficile</i>Antibiotic useOdds ratioNegative casesLarge-scale longitudinal dataFinancial incentivesPositive testLogistic regressionPatientsIncreased susceptibilityCharacteristic curveRegression modelsSignificant covariatesRetrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection
Knapple W, Yoho D, Sheh A, Thul J, Feuerstadt P. Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection. Therapeutic Advances In Gastroenterology 2024, 17: 17562848241239547. PMID: 38529070, PMCID: PMC10962041, DOI: 10.1177/17562848241239547.Peer-Reviewed Original ResearchClostridioides difficile</i> infectionSustained clinical responseClinical responsePrevention of recurrent CDITreatment successRecurrent Clostridioides difficile infectionConsistent with clinical trialsAlternative routes of administrationRetrospective subgroup analysisClostridioides difficile infectionReal-world safetyRoute of administrationFood and Drug AdministrationAnalysis of fecal microbiotaCDI recurrenceSingle-doseFecal microbiotaDifficile infectionAdverse eventsRetrospective analysisLive biotherapeutic productsColonoscopyDrug AdministrationClinical interestTEAEsFrailty is a predictor for worse outcomes in patients hospitalized with Clostridioides difficile infection
Chaar A, Yoo J, Nawaz A, Rizwan R, Agha O, Feuerstadt P. Frailty is a predictor for worse outcomes in patients hospitalized with Clostridioides difficile infection. Annals Of Gastroenterology 2024, 37: 442-448. PMID: 38974087, PMCID: PMC11226747, DOI: 10.20524/aog.2024.0898.Peer-Reviewed Original ResearchHospital Frailty Risk ScoreHealthcare resource utilizationHigher healthcare utilizationAdministrative billing dataPrimary diagnosis of CDIFrailty Risk ScoreNational Inpatient SampleHigher healthcare resource utilizationIntensive care unit admissionHealthcare utilizationClostridioides difficile</i> infectionFrailty statusDiagnosis of CDIRisk-stratify patientsHigher oddsClostridioides difficile infectionInpatient mortalityPerioperative risk assessmentHospital outcomesBilling dataRisk scoreInpatient SampleFrailtyAssessed differencesHealth implications
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply